Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

High dose radiation therapy linked to shorter survival times in NSCLC patients

A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway.

29 Oct 2020

Study finds persistence of racial disparities in treatment for common lung cancer

Lung cancer continues to be the most deadly solid cancer in the world, despite the fact that survival rates have been improving over the past decade.

28 Oct 2020

New tool can provide non-invasive decision support for NSCLC treatment

Personalized treatment options for patients with lung cancer have come a long way in the past two decades.

16 Oct 2020

New study may lead to more effective, personalized cancer immunotherapies

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.

12 Oct 2020

New initiative identifies key parameters underlying effective anti-tumor immunity

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies.

9 Oct 2020

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

5 Oct 2020

Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients

The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.

1 Oct 2020

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

An international team of researchers has found that selpercatinib, a drug that precisely targets cancers driven by mutations or alterations in the gene RET, was effective at shrinking tumours in patients with nonsmall cell lung cancer (NSCLC), with a majority of patients living for more than a year without disease progression.

28 Sep 2020

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers.

22 Sep 2020

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.

21 Sep 2020

Post-operative radiotherapy in NSCLC shows no statistically difference in 3-year disease-free survival

Post-operative radiotherapy (PORT) used in patients with non-small-cell lung cancer (NSCLC) following complete resection and after (neo) adjuvant chemotherapy shows no statistically significant difference in 3-year disease-free survival (DFS), according to data presented at ESMO 2020.

21 Sep 2020

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits.

21 Sep 2020

Study finds wide variation in levels and anti-tumor effectiveness of a common cancer drug

When used to manage infections, the drug itraconazole is generally given at a single, fixed dose to all patients.

17 Sep 2020

UofL receives $11.5 million to accelerate the development of new immunotherapies

Cancer remains one of the most difficult and deadly challenges in human health, affecting Kentuckians at a higher rate than residents of any other state and killing more than 600,000 people each year in the U.S. alone.

14 Sep 2020

Suppressing tumor's growth and spread from the inside

A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer, helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

3 Sep 2020

New diagnostic tool can predict cancer patients' response to immunotherapy

A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.

27 Aug 2020

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of participants in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

27 Aug 2020

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

The COVID-19 pandemic is still creating economic and health-related impact over the world. A new study published on the preprint server bioRxiv in August 2020 shows that a gp96-Ig-secreting vaccine candidate based on the expression of full-length spike protein generates a potent T cell response.

26 Aug 2020

Highly expressed protein in lung cancer cells drives resistance to targeted therapies

A protein highly expressed in lung cancer cells drives resistance to targeted therapies, report researchers at the Medical University of South Carolina in the Journal of Thoracic and Cardiovascular Surgery.

25 Aug 2020

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

7 Aug 2020

Non Small Cell Lung Cancer News and Research

High dose radiation therapy linked to shorter survival times in NSCLC patients

Study finds persistence of racial disparities in treatment for common lung cancer

New tool can provide non-invasive decision support for NSCLC treatment

New study may lead to more effective, personalized cancer immunotherapies

New initiative identifies key parameters underlying effective anti-tumor immunity

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients

Targeted therapy found to be effective at shrinking tumors in patients with nonsmall-cell lung cancer

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

Targeted therapy improves disease-free survival in patients with early-stage NSCLC

Post-operative radiotherapy in NSCLC shows no statistically difference in 3-year disease-free survival

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

Study finds wide variation in levels and anti-tumor effectiveness of a common cancer drug

UofL receives $11.5 million to accelerate the development of new immunotherapies

Suppressing tumor's growth and spread from the inside

New diagnostic tool can predict cancer patients' response to immunotherapy

Targeted therapy achieves durable objective responses Phase I/II LIBRETTO-001 trial

Heat Biologics SARS-CoV-2 vaccine generates potent T cell response in pre-clinical trial

Highly expressed protein in lung cancer cells drives resistance to targeted therapies

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News